Data Sheet (Cat.No.T8499)

TargetMol

eCF506

Chemical Properties



CAS No. : 1914078-41-3

Formula: C26H38N8O3

Molecular Weight: 510.63

Storage: Keep away from moisture,Store at low temperature
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Actual storage temperature shall be subject to the COA.

Biological Description

Description	eCF506 is a potent and selective inhibitor of SRC (IC50 < 0.5 nM)
Targets(IC50)	Src
In vitro	eCF506 can inhibit tyrosine kinase Src with IC50 value less than 0.5 nM.
In vivo	**METHODS**: Immunodeficient Rag2-Il2rg double knockout mice were implanted with PX459v2 and ILK gRNA 2 tumors and then given bosutinib (75 mg/kg) or eCF506 (40 mg/kg) once daily by oral gavage, and tumor volume growth was observed. **RESULTS** eCF506 treatment completely blocked the growth of ILK gRNA and PX459v2 tumors in the mouse model. [2]

Solubility Information

Solubility	DMSO: 52.5 mg/mL (102.81 mM),Sonication is recommended. (< 1 mg/ml refers to the product slightly soluble or insoluble)
In vivo Formulation	10% DMSO+40% PEG300+5% Tween 80+45% Saline: 2 mg/mL (3.92 mM),Sonication is recommended. *Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.*

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	1.9584 mL	9.7918 mL	19.5837 mL
5 mM	0.3917 mL	1.9584 mL	3.9167 mL
10 mM	0.1958 mL	0.9792 mL	1.9584 mL
50 mM	0.0392 mL	0.1958 mL	0.3917 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Reference

Fraser C, et al. Rapid Discovery and Structure-Activity Relationships of Pyrazolopyrimidines That Potently Suppress Breast Cancer Cell Growth via SRC Kinase Inhibition with Exceptional Selectivity over ABL Kinase. J Med Chem. 2016 May 26;59(10):4697-710.

Beetham H, et al. Loss of Integrin-Linked Kinase Sensitizes Breast Cancer to SRC Inhibitors. Cancer Res. 2022 Feb 15;82(4):632-647.